Use patterns for antipsychotic medications in medicaid patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 19, 1999, Pages 5-11

  McCombs, Jeffrey S ^a   Nichol, Michael B ^a   Stimmel, Glen L ^a   Shi, Jinhai ^a   Smith, Raymond R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DISULFIRAM; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE NEED; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CALIFORNIA; CLOZAPINE; COHORT STUDIES; DRUG COSTS; DRUG UTILIZATION; EPISODE OF CARE; HEALTH CARE COSTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSURANCE CLAIM REPORTING; MEDICAID; MULTIVARIATE ANALYSIS; RISPERIDONE; SCHIZOPHRENIA; UNITED STATES;

EID: 0032850678     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4): 1-63
2. Keith SJ, Regier DA, Rae DS. Schizophrenic disorders. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991:33-52
3. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72
4. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophr Bull 1998;24:11-20
5. Kissling W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry 1992;161(suppl):133-139
6. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995;21:567-577
7. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
8. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40. Correction 1993;13:149
9. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1996;154:457-465
10. Small JG, Hirsh SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
11. Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996;57(suppl 11):61-67
12. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57(suppl 9):66-76
13. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997;58(suppl 10): 50-54
14. Ho BC, Andreasen N, Flaum M. Dependence on public financial support early in the course of schizophrenia. Psychiatr Serv 1997;48:948-950
15. Johnstone BM, Croghan TW, Kessler RC, et al. Health insurance status and service utilization in a community sample of person with non-affective psychosis: the National Comorbidity Survey. Presented at the 125th Annual Meeting of the American Public Health Association: November 1997; Indianapolis, Ind
16. Kane JM. Treatment of schizophrenia. Schizophr Bull 1987;13:133-156
17. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia Schizophr Bull 1987;19:287-302
18. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
19. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
20. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chron Dis 1967;20:637-648
21. SAS Institute Inc. SAS Proc LOGISTIC, Version 6. Cary, NC: SAS Institute; 1993
22. Beasley CM, Tollefson GD, Tran PV, et al. Olanzapine versus placebo anc haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
23. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995;21: 579-591
24. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474
25. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia Am J Psychiatry 1994;151:825-835
26. Dellva MA, Tran PV, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-1577
27. Buckley PF. Treatment of schizophrenia: lets's talk dollars and sense. Am J Managed Care 1998;4:369-383